Study of a new pill for blood cancers with JAK2 V617F
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a new oral drug (ZE74-0282) for people with blood cancers that have a specific genetic change called JAK2 V617F. The goal is to see if the drug is safe and helps control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your blood cancer has a JAK2 V617F mutation (a specific genetic change).
- You have already tried treatment for your cancer, or you have decided not to have standard treatment.
- You are able to do most of your daily activities (score 0–2 on a standard scale).
- Your organs (liver and kidneys) are working well enough, based on blood tests.
- You are not pregnant or breastfeeding, and you agree to use birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental pill called PRT12396 for people with myeloproliferative neoplasms (MPN). It aims to see if the drug is safe and helps control the disease.
This study tests a new drug called LY5830966 for people with myelofibrosis whose disease has not responded to or has returned after treatment with a type I JAK2 inhibitor. The drug aims to help reduce symptoms and improve outcomes.
This study looks at a specific gene mutation in people with polycythemia vera (PV) or essential thrombocythemia (ET) to understand how it may relate to blood clots. It mainly involves collecting blood samples and joining a medical registry, before clot-lowering medicines start.
This trial tests a new drug, INCA035784, for people with myeloproliferative neoplasms (MPNs), a group of blood cancers. It may help if your MPN is called myelofibrosis (MF) or essential thrombocythemia (ET) and has a specific genetic change (CALR mutation), and you've already tried other treatments.
This trial tests a new pill for people with certain blood cancers that have not gotten better with standard treatments. It aims to see if the drug is safe and works, and it may help shrink tumors or slow the cancer.
This trial tests whether the drug ropeginterferon can help people with a JAK2 gene mutation who have additional risk factors but do not yet have a blood cancer. The goal is to see if treatment can prevent blood clots, high blood counts, or other complications.
Hear when a new Myelofibrosis (MF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.